AI assistant
Sending…
Novonesis AS — Director's Dealing 2024
Feb 2, 2024
3377_rns_2024-02-02_f7b11491-0092-4b8a-b3bb-2d9269bc9c96.pdf
Director's Dealing
Open in viewerOpens in your device viewer
novonesis
Trading by management and close relations of management
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the following transactions under ISIN DK0060336014, Novozymes B shares under the symbol NZYM B.
February 2, 2024
Company announcement No. 08
The Executive Leadership Team has on February 1st, 2024 from Novozymes A/S received the allocated shares from the incentive program for the period 2021-2023. An overview of the number and value of shares allotted is provided on the following pages.
Contact information
Investor Relations
Tobias Bjorklund +45 3077 8682 [email protected]
Anders Enevoldsen +45 5350 1453 [email protected]
About Novonesis
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.
Novozymes A/S, part of
Novonesis Group
Krogshoejvej 36
2880 Bagsvaerd
Denmark
novonesis.com
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Ester Baiget | |
| 2. | Reason for the notification | ||
| a) | Position/status | CEO and president | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | ||
| Identification code | B-Shares | ||
| DK0060336014 | |||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 14,923 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | |||
| - Price | Number of shares: 14,923 | ||
| Average price, DKK: 371.6 | |||
| Transaction value, DKK: 5,545,386.80 | |||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Amy Louise Byrick | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Human Health Biosolutions | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | ||
| Identification code | B-Shares | ||
| DK0060336014 | |||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 3,959 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | |||
| - Price | Number of shares: 3,959 | ||
| Average price, DKK: 371.6 | |||
| Transaction value, DKK: 1,471,164.40 | |||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Anders Lund | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Chief Operating Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | B-Shares | |
| Identification code | DK0060336014 | ||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 10,815 shares | ||
| d) | Aggregated information | Number of shares: 10,815 | |
| - Aggregated volume | Average price, DKK: 371.6 | ||
| - Price | Transaction value, DKK: 4,018,854.00 | ||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Claus Crone Fuglsang | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Chief Scientific Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | B-Shares | |
| Identification code | DK0060336014 | ||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 6,992 shares | ||
| d) | Aggregated information | Number of shares: 6,992 | |
| - Aggregated volume | Average price, DKK: 371.6 | ||
| - Price | Transaction value, DKK: 2,598,227.20 | ||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Morten Enggaard Rasmussen | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, People & Stakeholder Relations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | B-Shares | |
| Identification code | DK0060336014 | ||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 2,828 shares | ||
| d) | Aggregated information | Number of shares: 2,828 | |
| - Aggregated volume | Average price, DKK: 371.6 | ||
| - Price | Transaction value, DKK: 1,050,884.80 | ||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
Trading by management and close relations of management.
Company announcement No. 08
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Tina Sejersgård Fanø | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, Planetary Health Biosolutions | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novozymes A/S | |
| b) | LEI | 529900T6WNZXD2R3JW38 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | ||
| Identification code | B-Shares | ||
| DK0060336014 | |||
| b) | Nature of the transaction | Shares received as part of incentive program | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 371.6 | 10,815 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | |||
| - Price | Number of shares: 10,815 | ||
| Average price, DKK: 371.6 | |||
| Transaction value, DKK: 4,018,854.00 | |||
| e) | Date of transaction | February 1, 2024 | |
| f) | Place of the transaction | Outside a trading venue |
More from Novonesis AS
Director's Dealing
2026
May 6
Director's Dealing
2026
May 6
Director's Dealing
2026
Mar 26
Director's Dealing
2026
Mar 26
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 11
Director's Dealing
2026
Mar 11
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27